The incidence of congestive heart failure in the US population is increasing as more women and men survive with chronic hypertensive and atherosclerotic heart disease. Almost half the patients in the US with heart failure are women. Hypertension, diabetes mellitus, and cigarette smoking are all more potent risk factors for the development of heart failure in women than in men. Important differences in presentation and mortality explain gender differences in the clinical course of heart failure. Overall mortality is lower for women than for men with symptomatic heart failure. Some but not all of this difference can be explained by a lower rate of ischemic heart disease. Standard treatments for congestive heart failure, including angiotensin converting enzyme inhibitors and beta-blockers, have been shown to be equally efficacious in men and in women. Preliminary data on angiotensin II receptor blockers suggests equivalent benefit with further trial data awaited. Peripartum cardiomyopathy is a form of heart failure unique to women, occurring in the last stages of pregnancy or within 5 months after delivery. Approximately half of affected women regain normal ventricular function but for those who do not, the risk of recurrent symptomatic heart failure and mortality during subsequent pregnancies is high.
C ardiovascular disease is the leading cause of death in women, responsible for more deaths each year than all other causes combined. As treatment options have broadened and long-term survival improved, more women are surviving with chronic cardiovascular conditions such as hypertension and atherosclerotic heart disease. This improved survival has translated into a growing number of women with chronic congestive heart failure (CHF) of diverse etiologies.
Almost half of the patients in the United States with HF are women. Among persons older than 70 years, the incidence of CHF in women is higher than in men. 1, 2 
GENDER DIFFERENCES IN RISK FACTORS
Hypertension is a stronger risk factor for the development of CHF in women compared with men. In the Framingham study, hypertension conferred a 2-fold excess risk of developing HF in men and a 3-fold risk in women. 3 This observation has been duplicated in more recent studies and could be the result of a gender-based difference in cardiac response to pressure overload (see subsequently in this article).
Although the incidence of myocardial infarction (MI) is lower in women than in men, women who do sustain a MI are more likely to develop HF.
It is well known that diabetes mellitus is a more potent risk factor in women than in men for the development of atherosclerotic heart disease and that, in addition, diabetes increases the risk of death after an acute MI. Several studies 4 -6 have shown that diabetes mellitus is a stronger risk factor for the development of HF in women, with or without an ischemic etiology, as well.
The National Health and Nutrition Examination Survey Epidemiological Follow-Up Study 7 examined more than 13,000 men and women (5545 men and 8098 women) without evidence of CHF at baseline examination and followed them for an average of 19 years. A total of 1382 CHF cases were documented, of which 741 were men and 641 were women. Black women had a higher incidence of HF than white women. Cigarette smoking was a stronger risk factor for women than for men, conferring a 45% higher risk of HF in men and an 88% higher risk in women.
GENDER DIFFERENCES IN SURVIVAL
Discrepancies exist in the early literature regarding gender-based differences in survival in patients with CHF. Several studies have shown a better prognosis for women than for men with symptomatic CHF. In the Framingham study, 8, 9 the prognosis for women after the diagnosis of HF was better than for men (despite an older age at presentation) with a median survival of 3.2 years compared with 1.7 years. The short median survivals are reflective of the fact that patients were enrolled between 1948 and 1988, well before the widespread use of angiotensin-converting enzyme (ACE) inhibitors and beta blockers for the treatment of HF. In the Framingham study, echocardiographic estimation of left ventricular (LV) systolic function was not routinely obtained, and thus the HF population undoubtedly represents a heterogeneous array of differing physiological causes of HF.
In distinction to the early Framingham data, the Studies of Left Ventricular Dysfunction (SOLVD) Trial registry reported a poorer outcome in women than men presenting with symptomatic HF. 10 Over 6000 patients, including 1575 women, were enrolled in the registry between January 1988 and February 1989 and thus represent another cohort of patients experiencing HF treated before the widespread use of ACE inhibitors. Follow up in this registry report was limited to 1 year and found a 1-year mortality rate of 22% for women and 17% for men. Event-free survival was worse in women with an odds ratio of death or HF hospital admission for men compared with women of 0.67 (P Ͻ0.001). Women were older than men at study entry but had an equivalent depression of systolic function. Etiology of HF was not specified.
These seemingly disparate results could reflect the inclusion of patients with HF with preserved LV systolic function in the Framingham cohort and the probable inclusion of a greater percentage of women with ischemic heart disease in the SOLVD trial.
Although some of this gender-based survival advantage has been ascribed to the lesser prevalence of ischemic heart disease in women, mortality has been shown to be lower for women with HF in several large clinical trials after adjustment for differences in baseline variables. In the Metoprolol CR/XL Randomized Intervention Trial in Congestive Heart Failure (MERIT-HF) study, the relative risk for total mortality in the placebo arm was significantly lower for women as compared with men (relative risk, 0.63) regardless of HF etiology. 11 The influence of HF etiology on genderbased differences in survival was examined in 359 men and 112 women with optimally treated end-stage HF enrolled in the Flolan International Randomized Survival Trial (FIRST) and randomized to intravenous epoprostenol versus placebo. 12 After adjustment for important variables, including age, 6-minute walk test, dobutamine use at randomization, mean pulmonary artery pressure, and treatment assignment, significant gender-based differences in survival were noted. Among patients with a nonischemic etiology of HF, the relative risk of death for men versus women was 3.08 (95% confidence interval [CI], 1.56 -6.09), whereas among those with ischemic heart disease, the relative risk of death for men versus women was a modest and statistically insignificant 1.64 (95% CI, 0.87-3.09).
The University of North Carolina database has been in existence since 1984 and provides valuable information on the relationship among gender, etiology, and survival in patients with symptomatic HF. 13 A study of 557 patients (380 men and 177 women) with symptomatic HF, predominantly nonischemic in origin (68%), and severe LV dysfunction with a mean left ventricular ejection fraction (LVEF) of 25%, revealed a better survival in women compared with men when HF was the result of a nonischemic cause. The mean follow-up period was 2.4 years and the relative risk of death for men of 2.36 (P Ͻ 0.001). The risk of death was similar for the subset of men and women with ischemic heart disease as the primary cause of HF. Although baseline LVEF was higher in women than in men with nonischemic HF, the mortality in women remained lower after adjustment for this variable.
PREVENTIVE STRATEGIES
The Heart Outcomes Prevention Evaluation (HOPE) trial was a large, randomized, placebo-controlled trial that evaluated the ACE inhibitor ramipril in high-risk patients without clinical HF or known decrease in LV systolic function. This study enrolled 9297 patients, of whom 2545 were women. All participants in the trial were 55 years or older, had established vascular disease (involving the coronary, cerebral, or peripheral circulation) or diabetes mellitus plus one additional cardiovascular risk factor (elevated total cholesterol, low high-density lipoprotein cholesterol, hypertension, known microalbuminuria, or current cigarette smoking) and thus were considered high risk for the development of CHF.
The primary end point of the HOPE trial was a composite of MI, stroke, and cardiovascular death. The mean follow up was 4.5 years. Among women in this study, the primary end-point incidence was reduced from 14.9 to 11.3% (23% reduction). 14 The risk of stroke declined from 4.8 to 3.1% (36% reduction), and the risk of cardiovascular death from 6.9% to 4.2% (38% reduction). Additionally, there was a trend toward decreased incidence of MI, HF, and all-cause mortality. The beneficial effects of ACE inhibitor therapy were additive to other medications with known cardioprotective effects or favorable actions on cardiovascular risk factors, including beta blockers (taken by 34% of women in the HOPE trial), aspirin or other antiplatelet agents (taken by 64% of enrollees), and cholesterol-lowering agents (initially taken by 30%, increasing to 50% by the end of the study). The magnitude of observed benefit for ACE inhibition was similar in men and women.
At baseline, women were slightly older than men and were more likely to have a history of peripheral arterial disease, hypertension, diabetes mellitus, and hypercholesterolemia. They were less likely to have a history of coronary artery disease, previous MI, angina pectoris, or a prior revascularization procedure. Overall, men had worse outcomes when compared with women with a relative risk of reaching a primary end point of 1.34. This outcome difference persisted after adjustment for differences in baseline characteristics. 15 
TREATMENT OF ESTABLISHED HEART FAILURE

Angiotensin-Converting Enzyme Inhibitors
The first trial to demonstrate a survival benefit with the use of ACE inhibitors in HF was the Cooperative North Scandanavian Enalapril Survival Study (CONSENSUS) trial, reported in 1987. 16 A total of 253 patients with New York Heart Association (NYHA) class IV HF were enrolled in the trial of which 23% were women. Overall, the study demonstrated a significant mortality benefit at 6 and 12 months in men treated with enalapril in addition to digoxin and diuretic therapy. Although men experienced a 51% reduction in 6-month mortality, women achieved only a nonsignificant 6% reduction. 16A The small sample size undoubtedly contributed to this apparent discrepancy in survival benefit.
The Survival and Ventricular Enlargement (SAVE) trial enrolled 390 women with low LVEF following MI and suggested that ACE inhibitors might be less effective in women with HF. 17 Mortality risk reduction was 22% in men compared with 2% in women. Again, this result could be the result of the small number of women enrolled. After adjustment for baseline variables, risk reduction in men and women were similar (21 vs. 19%).
Early metaanalysis of ACE inhibitor trials 18 found significant reductions in mortality and the combined end point of all-cause mortality and hospitalizations for HF for men only. The apparent lack of benefit for women in this analysis most likely reflects the small 19 This metaanalysis incorporated data on 12,763 patients followed for an average of 35 months.
Beta Blockers
The Cardiac Insufficiency Bisoprolol (CIBIS II) study was the first large-scale randomized, double-blind, placebo-controlled European study to show a reduction in allcause mortality rates with the addition of the beta-1 selective antagonist bisoprolol to standard treatment with ACE inhibitors and diuretics. 20 A total of 2647 patients with New York Heart Association (NYHA) class III-IV HF and a LVEF of less than or equal to 35% were enrolled.
Of the total study population, 515 were women. As is often seen, the women were older than the men by approximately 5 years. They had a higher NYHA score with 21% versus 16% in class IV. Despite being sicker at baseline, women had a lower mortality rate after an average follow up of 1.3 years. The rates of sudden death, fatal MI, unknown cause of death, and all-cause hospital admissions did not differ between men and women.
MERIT-HF was a randomized, placebocontrolled study of metoprolol controlled-release/extended-release in 3991 patients with NYHA class II-IV HF resulting from LV systolic dysfunction. 21 The 2 primary outcome events were total mortality and the combined end point of all-cause mortality or all-cause hospitalization (time to first event). A total of 898 women were enrolled, compromising 23% of total enrollees in this trial, including 183 with severe HF (NYHA class III/IV symptoms and LVEF Ͻ26%) 22 . Analysis of this subgroup was recently reported. 23 Compared with men, women were older, were more often in NYHA class III and IV, less often classified as previous or current smokers, and had similar LVEFs. They had a higher prevalence of hypertension and diabe-tes mellitus and a lower prevalence of ischemic heart disease and prior MI. 10 Overall, treatment with extended-release metoprolol led to a 21% decrease in the combined end point of all-cause hospitalization and all-cause mortality in women, but did not lead to a significant reduction in mortality when viewed as a separate end point. There was a 29% decrease in cardiovascular hospitalizations and a 42% decrease in hospitalization resulting from worsening HF. In the subset of women with severe HF, there was a 44% reduction in the combined end point, a 57% reduction in cardiovascular hospitalization, and a 72% reduction in hospitalization resulting from worsening HF. In contrast to women, actively treated men had a significant but less robust reduction in all-cause hospitalization rates. A significant reduction in all-cause mortality was seen with actively treated men.
Although there was no significant survival advantage demonstrated in women who were randomized to beta blocker treatment in the MERIT-HF trial, this could be the result of the relatively small number of women enrolled and the small number of deaths in women, which totaled 64. A pooling of mortality results from 3 recent large beta blocker trials (MERIT-HF, CIBIS II, and Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS), providing the statistical power of a large sample size of more than 8900 patients, showed very similar survival benefits in women and men treated with beta blockers. 10
Other Vasodilators
ACE inhibitor use is recommended in all patients with reduced LV systolic function, regardless of the absence, presence, or severity of symptoms. However, a significant number of people develop intolerable side effects from these medications, limiting their use. Alternative vasodilator medications for patients who are intolerant of ACE inhibitors include the nonspecific vasodilating combination of hydralazine and isosorbide (as studied in the V-HeFT I trial) 24 and angiotensin II receptor blockers (ARBs), which have been more extensively studied. The V-HeFT trials, conducted in the Veterans Administration hospitals, included no women.
The Val-HeFT trial 25 studied the ARB valsartan versus placebo in combination with digoxin, diuretics, and beta blockers in 5010 patients (20% of whom were women) with class II-IV HF resulting from LV systolic dysfunction. Although overall mortality was similar in the 2 groups, there was a 13.2% reduction in the combined end point of morbidity and mortality defined as mortality plus the incidence of cardiac arrest with successful resuscitation, hospitalization for HF requiring intravenous inotropic, or vasodilator therapy. Similar benefit was seen in women and men.
The Candesartan Cilexetil in Heart Failure Assessment of Reduction in Mortality and Morbidity (CHARM) trial is comparing the ARB candesartan to either ACE inhibitor or placebo in 3 distinct HF patient populations, those with reduced LVEF either receiving or intolerant of ACE inhibition and those with clinical HF despite a preserved LVEF. This trial, which is ongoing, has enrolled 7601 patients. Although women represent 32% of the total enrollment, they compromise 40% of the subset with HF despite preserved LV systolic function. Preliminary evaluation 26 has concluded that women with HF are older than men (mean age, 68 vs. 65 years), are more likely to have a hypertensive etiology for their HF (21 vs. 9%), and are less likely to be treated with beta blockers (57 vs. 52%). At baseline, women were also found to have more symptoms and clinical evidence of systemic and pulmonary vascular congestion despite a higher LV ejection fraction (43% vs. 37%). The CHARM study treatment period is scheduled to be completed in March 2003, and final results will examine a combined end point of cardiovascular death or hospitalization for HF management.
CLINICAL TRIALS VERSUS CLINICAL PRACTICE
Although women have represented on average only 20% of patients enrolled in large trials of HF, 27 they represent a substantially larger percentage of HF patients seen clinically, in either general or specialty clinics, in either the inpatient or the outpatient setting. The Henry Ford Health System in the Detroit metropolitan area has published epidemiologic data on 29,686 patients with CHF in the Resource Utilization Among Congestive Heart Failure (REACH) study, providing a valuable insight into the role of chronic HF in the general U.S. population. 28 Their data are consistent with other studies in supporting the notion that the aging of the population and therapeutic advances are leading to an epidemic of HF in North America. A total of 52.6% of their patients were women who were, on average, 3.4 years older than their male counterparts at the time of entry into the HF database. Although women were predominant in the group Ͼ85 years of age, men consistently had higher incident rates yet poorer survival compared with women. The overall median survival for CHF in REACH was 4.5 versus 3.7 years for women and men, respectively. Age-adjusted survival was also significantly better for women compared with men. Overall survival must be interpreted with knowledge of the fact that 39.7% of all REACH patients who developed CHF past the age of 75 would be expected on the basis of age alone to have a lower survival when compared with their younger cohorts.
GENDER AND CARDIAC PHYSIOLOGY
A growing body of basic and clinical data points to fundamental gender-related differences in the nature and extent of myocardial hypertrophy and adaptation, which might account for the survival advantage for women. Early studies of spontaneously hypertensive rats suggested the adverse influence of hypertrophy on cardiac function was greater in male than female rats. 29 Gender differences in upregulation of LV ACE activity during pressure overload hypertrophy have been reported. 30 Importantly, gender has been found to influence the nature of LV adaptation in patients with aortic stenosis 341 Heart Failure in Women CARDIOLOGY IN REVIEW with women more likely to have well-preserved systolic function and less ventricular dilatation and hypertrophy than their male counterparts. 31 A similar situation exists with regard to hypertension with women more likely have LV hypertrophy 32
PERIPARTUM CARDIOMYOPATHY Epidemiology
Because peripartum cardiomyopathy (PPCM) very specific type of nonischemic cardiomyopathy relates only to women, it is appropriate to include a brief discussion for this review. The incidence of PPCM is in the order of 1 in 3000 to 4000 live births 33 The patients present with an array of symptoms nearly identical to other patients with decompensated HF, including dyspnea on exertion and fatigue, among others. The diagnosis can become difficult because these same symptoms can occur in the last trimester of pregnancy and be unrelated to any cardiac cause. HF symptoms can appear either during the third trimester of pregnancy or after delivery. Risk factors associated with PPCM include advanced maternal age, multiparity, black race, preeclampsia, and hypertension during pregnancy. 34 An National Heart, Lung, and Blood Institute workshop has instituted 4 criteria for diagnosis 35 
Etiology
The etiology of PPCM remains uncertain. Possible causes include myocarditis, an abnormal immune response, an abnormal response to the hemodynamic changes of pregnancy, and the presence of proinflammatory substances such as tumor necrosis factor. 35
Symptoms and Signs
The symptoms of PPCM can include dyspnea, tachypnea, orthopnea, peripheral edema, cough, and fatigue. A focused physical examination is most important and should include careful assessment of jugular venous pressure by neck vein examination, auscultation for the presence of a third heart sound (S3), murmur of mitral regurgitation, and any evidence of right-sided failure such as hepatomegaly and peripheral edema. An echocardiogram will be critical to make the appropriate diagnosis. Common echocardiographic findings include 4 ϭ chamber dilatation, biventricular hypokinesis, and mitral regurgitation resulting from LV dilatation. Additional possible findings can include intraventricular thrombus and the presence of pulmonary hypertension. 36
Therapy
Medical therapy is similar to that used in patients experiencing HF from other etiologies. 37 Nonpharmacologic therapy includes sodium and fluid restriction. In general, a 2-g daily sodium diet is reasonable and not unpalatable. Diuretics should be administered to maintain a euvolemic status as much as possible. Overdiuresis, hypokalemia, and hyponatremia should be avoided. The jugular venous pressure can serve as a guide to diuretic administration. Angiotensin-converting enzyme inhibitors (ACE I) need to be avoided early in pregnancy because of teratogenic effects. In the last trimester of pregnancy and especially in the peripartum period, ACE I can be used. During pregnancy, hydralazine and nitrates will serve safely as preload and afterload reducers and improve forward cardiac output as well as lower LV filling pressures. Digoxin can also be safely administered. Because beta blockers have become standard therapy for patients experiencing HF, these agents can also be administered as concomitant therapy once the patient is euvolemic. Beta blockers can also serve as antihypertensive agents. Bradycardia, however, should be avoided.
Occasionally patients can develop severe decompensation and require intravenous vasodilators such as nitroprusside or inotropes. Dopamine, dobutamine, or milrinone could be administered as short-term agents for support. In some instances, patient deterioration can occur and lead to listing for cardiac transplantation and/or ventricular assist support. 37 In summary, before delivery and in the peripartum period, keeping volume stable and aggressively treating hypertension are broad, sound guidelines. In general, vaginal delivery is preferred to avoid the risks of a hypercoagulable state. Routine anticoagulation is not necessary, but careful attention must be given to the presence of intraventricular thrombi on an echocardiogram, which could prompt heparin or warfarin therapy. Postpartum, ACEI should be certainly instituted as should beta blockers in a fashion similar to other patients experiencing HF.
Prognosis
Approximately 50% of patients normalize ventricular function shortly after delivery. If the ejection fraction has not improved by 6 months, recovery becomes doubtful. Some might quickly deteriorate requiring transplantation. 38 One of the major issues surrounding PPCM is that of subsequent pregnancies. To date, there are no prospective trials that have addressed this issue directly. Recently, Elkayam et al. published a registry of survey forms sent to cardiologists/HF specialists. 39 Group 1 consisted of women whose ventricular function had normalized after having experienced PPCM and before a subsequent pregnancy. Group 2 consisted of women who had persistent LV dysfunction before the subsequent pregnancy. The group that did not totally normalize ejection fraction were more likely to have a drop in ejection fraction during the next pregnancy. The deaths that occurred during follow up were more likely to be in group 2.
Based on this registry, women who have had PPCM should be discouraged from becoming pregnant again and especially if the ventricular function did not normalize after the first HF event.
